Abstract. The prognosis for advanced gastric cancer remains very poor due to the limited effectiveness of chemotherapy agents. The range in efficacy of these chemotherapy agents is likely the result of various factors including gene expression. In addition, the emergence of drug resistance during chemotherapy can result in the undesirable outcome of patients experiencing the side effects of chemotherapy without benefiting in terms of tumor response. Gene expression profiling provides a unique opportunity to gain insight into the development of different types of gastric cancer. We applied the TaqMan low density array to investigate the expression of 96 genes in four gastric cancer cell lines (TMK-1, MKN-45, MKN-74 and CDDP-resistant MKN-74). The cell lines displayed different patterns of gene expression alteration after exposure to the chemotherapeutic drugs cisplatin and 5-fluorouracil. We also established that cisplatin-resistant MKN-74 cells do not show the same gene expression patterns as the parental MKN-74 cell line at 0, 8 and 24 h after CDDP exposure. This study reveals the underlying complexity of biological and pathological events and could, perhaps, contribute to new experimental protocols or treatments that would achieve a consistent and desirable outcome of chemotherapy.
Introduction
Gastric cancer is the fourth most common cancer world-wide (1) . Although early gastric cancer, which is defined as a tumor confined to the mucosa or submucosa, has a 5-year survival rate exceeding 90% in Japan, the prognosis for advanced gastric cancer (AGC) remains poor. Surgical resection is the most powerful tool to overcome AGC, and recent studies suggest that systemic chemotherapy after surgery might improve the prognosis of AGC patients (2) . A previous study showed that chemotherapy for metastatic gastric cancer yields a significant survival benefit, compared with that of best support care without chemotherapy (3) .
Cisplatin (CDDP) and 5-fluorouracil (5-FU) are the key therapeutic agents for AGC; whereas, chemotherapy with single agents only achieves a response rate of 10-20% (4, 5) in AGC. The difference between an effective and an ineffective response to anticancer drugs in AGC is likely dependent on various factors including polymorphisms, gene expression profiles in cancer cells (6, 7) and several host factors. In addition, the emergence of drug resistance after chemotherapy can result in an undesirable outcome in AGC because many cancer patients suffer from the adverse effects of chemotherapy without any benefit in terms of tumor response.
Theoretically, the two major mechanisms of drug resistance are i) intrinsic resistance, in which untreated tumor cells are inherently insensitive to the chemotherapeutic agent and ii) acquired resistance, in which treated tumor cells become insensitive after drug exposure (8) . It is well known that acquired drug resistance is caused by many factors such as host metabolism, the genetic nature of cancer cells or epigenetic changes of cancer cells, accompanied by numerous molecular events (9) .
Several studies have recently suggested that there are dynamic alterations in gene expression evoked by several exogenous stimulators such as cytokines or chemotherapeutic agents in normal and cancer cells (10) (11) (12) (13) (14) and drug sensitivity/resistance has been predicted by measuring baseline expression levels of chemoresistance-related genes without such exogenous stimulation. The dynamics of gene expression should be interpreted in context with all biological behaviors in normal and cancer cells. An understanding of the changes in gene expression in cancer cell lines with and without treatment could shed light on the complexity of biological and pathological processes, perhaps leading to successful experimental protocols or treatments that produce a desirable outcome with, for example, chemotherapy.
The Taqman low density array system used in this study is a novel tool for quantifying gene expression (15, 16 (Table I) . Real-time reverse transcription polymerase chain reaction (RT-PCR) analysis was performed using the Applied Biosystems micro fluidic card according to the manufacturer's instructions. In brief, 2.5 μg of total RNA was reverse transcribed using the High Capacity cDNA archives kit and MultiScribe reverse transcriptase (Applied Biosystems). The reaction mixtures were incubated initially at 25˚C for 10 min and subsequently at 37˚C for 120 min. Quantitative PCR (TaqMan) assays were performed using the Micro fluidic card system incorporating Assays-On-Demand (Applied Biosystems), a pre-validated library, into 384-well micro fluidic cards. One hundred ng of cDNA samples, along with 50 μl of 2x PCR master mix, were loaded into each channel on the micro fluidic card, followed by a brief centrifugation. The card was then sealed, and real-time PCR and relative quantification were performed using an ABI PRISM 7900 sequence detection system (Applied Biosystems). The expression of each gene was normalized using ß-actin as a reference, and the relative expression levels were qualified using the ΔCt method (Applied Biosystems) (20) . All RNA extractions were carried out in triplicate. Data are expressed as average ratio (n=3) ralative control.
Statistical analysis. Statistical analysis was performed using Student's t-test, and a significance level of P<0.05 was regarded as statistically significant. Time-dependent alteration of gene expression in TMK-1 (Table II and Fig. 1 ). For TMK-1 cells, of the 96 genes on the array, 65 genes in the CDDP treatment group and 63 genes in the 5-FU treatment group were successfully quantified before and after drug exposure. The expression of 7 genes was significantly up-regulated at 8 h after CDDP treatment, and the number of up-regulated genes increased to 41 at 24 h after CDDP exposure. The expression of 3 genes was downregulated 8 and 24 h after CDDP exposure. For 5-FU treatment, no genes were found to be up-regulated at 8 h, but the Table I . The genes investigated. Table I . Continued. (Table III and Fig. 2 ). For MKN-45 cells, of the 96 genes on the array, 52 genes were successfully quantified throughout the experiment with CDDP and 5FU exposure. The expression of 3 genes was up-regulated at 8 h after CDDP exposure, and 2 of these 3 genes showed enhanced expression at 24 h, while the other gene recovered to the baseline level. The number of up-regulated genes increased from 3 genes at 8 h to 13 genes at 24 h after CDDP exposure. The expression of 6 genes was down-regulated at 8 h after CDDP treatment; of these 6 genes, 3 genes recovered to Table I . Continued. (Table IV and Fig. 3) . For MKN-74 cells, of the 96 genes, 40 genes in the CDDP treatment group and 41 genes in the 5-FU Table II . Time-dependent alterations of gene expression in TMK-1. Up-regulated  After 8 h  UMPS, UNG, PCNA, CDC25A, YWHAG, CTNNB1, TUBB4  After 24 h  UMPS, RRM1, RRM2, ERCC1, UNG, ADPRT, TOP1, TOP2A, TOP2B, HSPB1, E2F1, TP53,  PCNA, HIF1A, CCNB1, CCNE1, CCND1, CDC2, CDC25A, CDK2, CDK4, CDK7, CDKN1A,  CDKN1B, DDI2,GADD45A, PDCD8, YWHAG, ABCC2, ABCG2, CREB1, CTNNB1, GSTP1,  GSR, IL15RA, JUN, MYC,RB1, STAT1, STAT3, TUBB4 Down-regulated 
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member -----------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------a. CDDP
After 8 h CDKN1A, GADD45A, GADD45G After 24 h RRM2B, HSPB1, TP53, ITGA3, PCNA, CCNE1, CDKN1A, CDKN1B, GADD45A, GADD45B, YWHAG, CTNNB1, TUBB4
After 8 h ID4, CDKN1A, GADD45B, ABCC5 After 24 h ID4, ATM, CDC25A, CDKN1A, GADD45G, ABCC5, VEGF Down-regulated  After 8 h  UMPS, RRM2, ERCC1, UNG, TOP1, TOP2B, HSPB1, TP53, HIF1A, CCNB1, CCNH,  CDC2, CDK2, PDCD8, PRKDC, ABCG2, CREB1, CTNNB1, GSR, MYC  After 24 h  RRM2B, ERCC1, UNG, TOP1, TOP2B, TP53, HIF1A, CCNB1, CCNH, CDC2, CDK2,  CDKN1B, PDCD8, PRKDC, YWHAG, ABCG2, CDH1, CREB1, CTNNB1, GSR, 
treatment group were successfully quantified. Nine genes were up-regulated at 8 h after CDDP exposure, and 24 genes were up-regulated at 24 h after CDDP exposure. Eleven genes were down-regulated at 8 h after CDDP exposure, and this number decreased to 3 genes at 24 h after CDDP exposure. For 5-FU treatment, 7 genes were up-regulated at 8 h, and 6 of these 7 genes showed enhanced up-regulation at 24 h after 5-FU exposure; the seventh returned to baseline at 24 h after 5-FU exposure. A total of 17 genes were up-regulated at 24 h after 5-FU exposure. On the other hand, 20 genes were downregulated at 8 h after 5-FU exposure; out of these 20 genes, the expression of 10 genes recovered to baseline, while 6 genes remained down-regulated and 4 genes showed up-regulation (compared to baseline levels) at 24 h after 5-FU exposure. (Tables V and VI; Figs. 4 and 5) . CDDP-resistant MKN-74 cells without drug exposure showed up-regulation in 21 genes and downregulation in 24 genes compared with the parental MKN-74 cell line (Table V) .
Gene analysis of CDDP-resistant MKN-74
Of the 96 genes on the array, 44 genes were successfully evaluated after CDDP exposure. The substantial differences in gene alteration by CDDP were confirmed between the ONCOLOGY REPORTS 21: 451-459, 2009 Table IV . Time-dependent alterations of gene expression in MKN-74. Up-regulated  After 8 h  ERCC1, HSPB1, TP53, CDKN1A, DDIT3, GADD45A, ABCG2, CTNNB1, JUN  After 24 h  ID4, IGF2, RRM2B, RRM2, ERCC1, HSPB1, TP53, CDK4, CDKN1A, CDKN1B,CDKN2A,  DDIT3, GADD45A, GADD45B, GADD45G, YWHAG, ABCG2, CDH1, CREB1, CTNNB1,  JUN, NOTCH1, RB1, STAT3   Down-regulated  After 8 h  TYMS, UMPS, UNG, TOP1, TOP2B, CCND1, DNMT1, GSTP1 , GSR, MYC, STAT1
After 8 h IGF2, RRM2B, HSPB1, CDKN1B, CDH1, CREB1, PTGS2 After 24 h IGF2, RRM2B, UMPS, RRM1, UNG, TOP1, SLC29A1, TOP2B, HSPB1, HIF1A, CDKN1B, CDKN2A, CHEK1, GADD45B, CREB1, MYC, PTGS2
Down-regulated After 8 h ID4, TYMS, UMPS, RRM1, RRM2, UNG, CCND1, CDK4, CHEK1, GADD45A GADD45G, YWHAG, CTNNB1, DNMT1, GSR, JUN, NOTCH1, RB1, STAT1, STAT3 After 24 h GADD45A, GADD45G, DNMT1, GSR, JUN, STAT1, Table V . Gene analysis of CDDP-resistant MKN-74 relative to MKN-74 at 0 h. Increase in expression  ID4, HSPB1, TOP2B, E2F1, PCNA, ATM, CCNA2, CCNB1,  CCNH, CDC2, CDC25A, CDK2, CDK7, CDKN2A, PDCD8,  PRKDC, DNMT1, GSTP1, IL4, PTGS2, UBB4   Decrease in expression  IGF2, RRM2B, TYMS, UMPS, RRM1, RRM2, TP53,  HIF1A, CCND1, CDK4, CDKN1B, GADD45A, GADD45B,  GADD45G, YWHAG, ABCG2, CREB1, CTNNB1, GSR Several reports have suggested that the mechanisms of resistance against CDDP are not completely understood and seem to involve many factors (21, 22) . Modifications of CDDP metabolism inside cells, drug transportation, enhanced intracellular detoxification or increased repair and/or tolerance to DNA damage are possible mechanisms of CDDP resistance with various molecular changes (23) (24) (25) (26) . However, such mechanisms were only discussed relating to acquired-resistance cells; and in the field of chemosensitivity/ chemoresistance in cancer cells, dynamic alterations of genes at the mRNA level have not yet been in focus. This study has uniquely shown various kinds of gene alteration after chemotherapy among different gastric cancer cell lines and between acquired CDDP-resistant cell lines and the parental cell line. This suggests that complex interactions involving many genes and genetic and epigenetic phenotypes occur after anticancer drug exposure. However, some genes with altered expression by CDDP or 5-FU are not necessarily directly related to sensitivity or resistance to CDDP; thus, some of the gene alterations evaluated with the present array include incidental alteration (27) .
Recent trials to predict chemosensitivity using analysis of chemosensitivity/chemoresistance-related genes, such as thymidine synthase, dihydropyrimidine dehydrogenase or ATP binding cassette family, are reported to have good potential for clinical use (28) (29) (30) ; however, our demonstration of the dynamic alteration of gene expression after anticancer drug exposure will completely deny the role of prediction of chemotherapeutic outcome by a one-point measurement of baseline gene expression, especially without a specific therapy. Furthermore, this study suggests that, even among gastric cancer patients, various gene dynamics will occur, suggesting clinical difficulties in predicting chemotherapeutic outcome by measuring dynamic gene expression alteration even in one kind of cancer cell after one kind of chemotherapy. Interestingly, recent work on gene dynamics in fetal development, immunity, and the stem cell field has shown similar results. This recent study suggests that cancer cells themselves are adapting to the altered microenvironment induced by anticancer drugs (31) (32) (33) (34) . Ultimately, prediction of chemotherapeutic outcome in clinics should include baseline values and dynamic values of complex gene expression with drug exposure, as well as host dynamics such as drug distribution, metabolism, and toxicity with drugs. In this study, the focus on the in vitro human cancer cell line system, neglecting host factors, highlights the biological significance of understanding gene expression dynamics especially in cancer cells, as well as the inherent biological nature of cancer cells. This study may provide a foundation for the development of new treatments or experimental protocols, focusing on the complexity of biological and pathological events, to achieve a desirable outcome of chemotherapy.
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